Teva Pharmaceutical (TEVA) Tops Q1 EPS by 3c, Sales Light

Teva Pharmaceutical (NASDAQ: TEVA) reported Q1 EPS of $1.47, $0.03 better than the analyst estimate of $1.44. Revenue for the quarter rose 25% to $5.1 billion versus the consensus estimate of $5.51 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold
• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral